S&P 500   4,571.64 (+0.49%)
DOW   36,054.01 (+0.00%)
QQQ   389.69 (+1.21%)
AAPL   194.62 (+1.20%)
MSFT   368.18 (-0.17%)
META   324.68 (+2.28%)
GOOGL   136.69 (+5.13%)
AMZN   146.66 (+1.48%)
TSLA   243.83 (+1.86%)
NVDA   462.94 (+1.74%)
NIO   7.56 (-2.45%)
BABA   72.12 (+0.88%)
AMD   125.45 (+7.39%)
T   17.00 (+0.35%)
F   10.83 (+1.31%)
MU   73.75 (+0.85%)
CGC   0.71 (+1.20%)
GE   119.06 (-0.63%)
DIS   93.22 (+1.88%)
AMC   6.86 (+1.03%)
PFE   28.61 (-0.63%)
PYPL   58.79 (-1.24%)
XOM   99.90 (+0.80%)
S&P 500   4,571.64 (+0.49%)
DOW   36,054.01 (+0.00%)
QQQ   389.69 (+1.21%)
AAPL   194.62 (+1.20%)
MSFT   368.18 (-0.17%)
META   324.68 (+2.28%)
GOOGL   136.69 (+5.13%)
AMZN   146.66 (+1.48%)
TSLA   243.83 (+1.86%)
NVDA   462.94 (+1.74%)
NIO   7.56 (-2.45%)
BABA   72.12 (+0.88%)
AMD   125.45 (+7.39%)
T   17.00 (+0.35%)
F   10.83 (+1.31%)
MU   73.75 (+0.85%)
CGC   0.71 (+1.20%)
GE   119.06 (-0.63%)
DIS   93.22 (+1.88%)
AMC   6.86 (+1.03%)
PFE   28.61 (-0.63%)
PYPL   58.79 (-1.24%)
XOM   99.90 (+0.80%)
S&P 500   4,571.64 (+0.49%)
DOW   36,054.01 (+0.00%)
QQQ   389.69 (+1.21%)
AAPL   194.62 (+1.20%)
MSFT   368.18 (-0.17%)
META   324.68 (+2.28%)
GOOGL   136.69 (+5.13%)
AMZN   146.66 (+1.48%)
TSLA   243.83 (+1.86%)
NVDA   462.94 (+1.74%)
NIO   7.56 (-2.45%)
BABA   72.12 (+0.88%)
AMD   125.45 (+7.39%)
T   17.00 (+0.35%)
F   10.83 (+1.31%)
MU   73.75 (+0.85%)
CGC   0.71 (+1.20%)
GE   119.06 (-0.63%)
DIS   93.22 (+1.88%)
AMC   6.86 (+1.03%)
PFE   28.61 (-0.63%)
PYPL   58.79 (-1.24%)
XOM   99.90 (+0.80%)
S&P 500   4,571.64 (+0.49%)
DOW   36,054.01 (+0.00%)
QQQ   389.69 (+1.21%)
AAPL   194.62 (+1.20%)
MSFT   368.18 (-0.17%)
META   324.68 (+2.28%)
GOOGL   136.69 (+5.13%)
AMZN   146.66 (+1.48%)
TSLA   243.83 (+1.86%)
NVDA   462.94 (+1.74%)
NIO   7.56 (-2.45%)
BABA   72.12 (+0.88%)
AMD   125.45 (+7.39%)
T   17.00 (+0.35%)
F   10.83 (+1.31%)
MU   73.75 (+0.85%)
CGC   0.71 (+1.20%)
GE   119.06 (-0.63%)
DIS   93.22 (+1.88%)
AMC   6.86 (+1.03%)
PFE   28.61 (-0.63%)
PYPL   58.79 (-1.24%)
XOM   99.90 (+0.80%)

Amphastar Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMPH)

$57.39
-0.86 (-1.48%)
(As of 11:09 AM ET)
Compare
Today's Range
$56.06
$58.36
50-Day Range
$44.49
$59.92
52-Week Range
$27.58
$67.66
Volume
127,229 shs
Average Volume
393,539 shs
Market Capitalization
$2.75 billion
P/E Ratio
22.42
Dividend Yield
N/A
Price Target
$68.00

Amphastar Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
18.5% Upside
$68.00 Price Target
Short Interest
Bearish
8.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.21
Upright™ Environmental Score
News Sentiment
0.35mentions of Amphastar Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.02 M Sold Last Quarter
Proj. Earnings Growth
17.87%
From $2.91 to $3.43 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

60th out of 958 stocks

Pharmaceutical Preparations Industry

12th out of 394 stocks


AMPH stock logo

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Stock Price History

AMPH Stock News Headlines

3 Best Momentum Stocks to Buy Using the Driehaus Strategy
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Needham Keeps Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
Q3 2023 Amphastar Pharmaceuticals Inc Earnings Call
See More Headlines
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMPH
Employees
1,615
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$68.00
High Stock Price Target
$71.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+19.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$91.39 million
Pretax Margin
28.48%

Debt

Sales & Book Value

Annual Sales
$498.99 million
Cash Flow
$2.32 per share
Book Value
$10.94 per share

Miscellaneous

Free Float
34,589,000
Market Cap
$2.72 billion
Optionable
Optionable
Beta
0.93
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives















AMPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMPH shares.
View AMPH analyst ratings
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 12-month price targets for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $63.00 to $71.00. On average, they expect the company's stock price to reach $68.00 in the next year. This suggests a possible upside of 18.5% from the stock's current price.
View analysts price targets for AMPH
or view top-rated stocks among Wall Street analysts.

How have AMPH shares performed in 2023?

Amphastar Pharmaceuticals' stock was trading at $28.02 at the beginning of the year. Since then, AMPH stock has increased by 104.8% and is now trading at $57.39.
View the best growth stocks for 2023 here
.

Are investors shorting Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,890,000 shares, an increase of 15.6% from the October 31st total of 2,500,000 shares. Based on an average trading volume of 450,200 shares, the days-to-cover ratio is currently 6.4 days. Currently, 8.1% of the shares of the stock are sold short.
View Amphastar Pharmaceuticals' Short Interest
.

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our AMPH earnings forecast
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings data on Wednesday, November, 8th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.67 by $0.41. The firm had revenue of $180.56 million for the quarter, compared to analyst estimates of $170.65 million. Amphastar Pharmaceuticals had a net margin of 22.50% and a trailing twelve-month return on equity of 26.68%.

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (7.18%), Fuller & Thaler Asset Management Inc. (2.66%), Northern Trust Corp (1.17%), Morgan Stanley (1.17%), Jacobs Levy Equity Management Inc. (1.16%) and Invesco Ltd. (0.86%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends
.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AMPH) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -